The global HER2-positive gastric cancer market is currently valued at USD 1261.8 Million in 2023 and is anticipated to expand at a CAGR of 3.5%. Owing to the technological advances in healthcare the market is likely to propel to USD 1779.8 Million by 2033.
The increase in disease burden and approval of pipeline candidates are likely to drive the growth of the HER2 positive market in the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1261.8 Million |
| Projected Forecast Value (2033) | USD 1779.8 Million |
| Global Growth Rate (2023 to 2033) | 3.5% CAGR |
The HER2-positive gastric cancer market is expected to gain market growth in the forecast period of 2023 to 2033. Latest market analysis by FMI the market is to grow at a CAGR of 3.5% in the above-mentioned forecast period.
The stomach cancer cells have too much of a growth-promoting protein called HER2 on their surface. Cancers with increased levels of HER2 are called HER2-positive. Drugs that target the HER2 protein can often be helpful in treating these cancers.
Over the coming years, the soaring emphasis on the development of more effective treatment procedures and advanced drugs is projected to foster the HER2-positive gastric cancer market.
The Approval of New Targeted and Immunotherapy Drugs Is Expected to Fuel the Market Growth During the Forecast Period
The increasing incidence of adenocarcinoma, lymphoma, and gastrointestinal stromal tumors across the globe. Major drivers for the stomach cancer market are treatment advancements, combination therapies, an increasing number of cancer treatment centers
Quick approvals from the regulatory authorities regarding HER2-positive gastric cancer drugs may bring immense growth prospects for the gastric cancer drugs market. Research and development activities play an important role in developing novel drugs and therapies.
For instance, in January 2021, the USA FDA approved Enhertu, an antibody-drug conjugate product for treating HER-2-positive metastatic gastric cancers.
Increasing Healthcare Awareness to Boost the Market Growth
Health awareness amongst the population is rising which results in the prediction of drugs boosting the market growth. The innovative launches in medications for treating HER 2-positive gastric cancer are expected to prompt the market simultaneously.
Different researchers are investing in launching drugs that benefit the market. This creates more opportunities in the market. An increase in the incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma; a rise in alcohol consumption, a surge in smoking, and an increase in the geriatric population are anticipated to boost the growth of the global HER 2 positive gastric cancer testing market during the forecast period.
Stringent Government Regulation for Drug Approval May Restrain The Market Growth
Despite a positive growth trajectory, the global HER2-positive Gastric Cancer market is facing various challenges that are likely to pose a threat to its growth during the forecast period.
The lack of understanding of intratumoral heterogeneity, erosion in innovator sales, like the launch of biosimilars, and lack of universal guidelines for the assessment of HER2 overexpression or amplification may restrain the growth of the market during the forecast period.
The lack of adequate financial assistance from health insurance policies and stringent regulatory procedures for approving the complex nature of radiation devices are the major factors that can hamper the gastric cancer market growth over the forecast period.
Increasing cancer cases in the region drive the market growth in North America
North America dominated the market and accounted for the largest revenue share of around 3.4% in 2023. The rising prevalence of gastric cancer is driving the growth of the HER2-positive gastric cancer market in North America.
Gastric cancer is the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease.1,2 Approximately one in five gastric cancers are considered HER2 positive. An estimated 27,600 new cases of gastric cancer will be diagnosed this year and the disease could lead to more than 11,000 deaths in the USA in 2020.
Thus, the increasing number of gastric cancer cases in the region is expected to rise the demand for effective therapies for treating patients with gastric cancer which in turn is anticipated to fuel the market growth over the forecast period.
The rising adoption of targeted cancer therapy and the availability of advanced technology in cancer research and treatment centers boost the market growth in the region.
For instance, in May 2020 AstraZeneca and Daiichi Sankyo Company, Limited has been granted Orphan Drug Designation (ODD) in the USA for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
Increase in Significant Research and Development Investments in Healthcare to Boost the Market Growth
Europe is estimated to witness considerable growth during the forecast period due to increasing investments in the development of advanced treatment options and the rising target patient population.
Furthermore, the rising company activities in conducting clinical trials for developing effective drugs for patients suffering from HER2-positive gastric cancer as well as increasing product launches and approvals in the region are expected to fuel the market growth.
For instance, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
Advancement in Healthcare to Propel the Market Growth
Asia Pacific is anticipated to expand at the fastest CAGR of % during the forecast period. Rapid growth in global demand for drugs has encouraged major drug manufacturers to set up facilities for manufacturing Research and Development in this region. Initiatives undertaken by various organizations to create awareness, educate people, and raise funds for the disease are anticipated to propel regional growth.
Furthermore, advancements in healthcare infrastructure, rising government spending on healthcare policies, and the presence of important members in Asia Pacific all contribute to the growth of the global HER2-positive gastric cancer market.
Country-wise Forecast CAGRs for the HER2 Positive Gastric Cancer Market
| The UK | 3.3% |
|---|---|
| India | 3.1% |
| South Korea | 3.3% |
| China | 3.2 % |
| The USA | 3.4 % |
Targeted Therapy Segment remains dominant among other types
Based on the therapy, the targeted therapy accounted for the largest market share in 2023. This is attributed to the increased adoption of targeted therapy along with the chemotherapy and rise in awareness regarding combination therapies for gastric cancer. HER-2 inhibitor trastuzumab is the only molecular targeted drug approved by the USA Food and Drug Administration (FDA) for the first-line treatment of HER-2-positive advanced gastric cancer. The segment held a revenue share of over 55.4% in 2023
Therefore, the rising prevalence of gastric cancer and increased usage of targeted therapy in combination with different other therapies has fostered the growth of this segment in the past few years.
Immunotherapy is estimated to be the fastest-growing segment during the forecast period. The rising awareness among patients regarding the effectiveness and benefits of immunotherapy over chemotherapy is expected to boost the growth of this segment. The growing focus of the manufacturers and the active participation of the authorities like the FDA and EMA in the approval of immunotherapy drugs is expected to augment the demand for immunotherapy drugs for the treatment of Her2-positive gastric cancer.
Hospital and Speciality Clinics Dominated the Market
The Hospital and speciality clinics segment dominated the Her 2 positive gastric cancer therapy market in 2023 with a revenue share of over 35.0%. Initiatives by regional governments to develop healthcare infrastructure is expected to drive the segment growth during the forecast period. Based on the end-user, the market has been segmented into hospitals and speciality and ambulatory surgery centres.
The ambulatory surgery centre segment accounted for the second-largest share in 2021. Most patients with gastric cancer undergo inpatient administration of treatment in developing nations. This is one of the major factors fueling the growth of this segment.
How do New Entrants Contribute to the HER2 Positive Gastric Cancer Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the HER2-positive Gastric Cancer market.
Some of the start-ups in the HER2-positive Gastric Cancer market include-
Key pharmaceutical companies that are working efficiently in the HER2-positive Gastric Cancer space include names like AstraZeneca, Bayer, Bristol-Myers Squibb, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Sanofi, Pfizer, Novartis AG, and others.
The manufacturers are involved in the production of HER2-positive Gastric Cancer in a larger capacity. Research and innovation are also conducted to launch innovative products for HER2-positive Gastric Cancer.
Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR 3.5% from 2023 to 2033 |
| Expected Market Value (2023) | USD 1261.8 Million |
| ProjectedForecast Value (2033) | USD 1779.8 Million |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive L&scape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered | Therapy, Stage, End-user, Regions |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; Asia-Pacific; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Benelux, France, Germany, Italy, Nordic, Spain, The UK, Poland, Russia, India, Malesia, Singapore, Thailand, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | AstraZeneca; Bayer; Bristol-Myers Squibb; Ono Pharmaceutical Co. Ltd; Hutchison Medipharma; LintonPharm; Shanghai Henlius Biotech; Sanofi; Pfizer; Novartis AG |
| Customization | Available Upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Stage, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Stage, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Stage, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Western Europe Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 15: Western Europe Market Value (US$ Million) Forecast by Stage, 2018 to 2033
Table 16: Western Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Eastern Europe Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 19: Eastern Europe Market Value (US$ Million) Forecast by Stage, 2018 to 2033
Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 21: APAC Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: APAC Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 23: APAC Market Value (US$ Million) Forecast by Stage, 2018 to 2033
Table 24: APAC Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 25: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: MEA Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 27: MEA Market Value (US$ Million) Forecast by Stage, 2018 to 2033
Table 28: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Stage, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Stage, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 17: Global Market Attractiveness by Therapy, 2023 to 2033
Figure 18: Global Market Attractiveness by Stage, 2023 to 2033
Figure 19: Global Market Attractiveness by End User, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Stage, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Stage, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 37: North America Market Attractiveness by Therapy, 2023 to 2033
Figure 38: North America Market Attractiveness by Stage, 2023 to 2033
Figure 39: North America Market Attractiveness by End User, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Stage, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Stage, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Therapy, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Stage, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Western Europe Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 62: Western Europe Market Value (US$ Million) by Stage, 2023 to 2033
Figure 63: Western Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Western Europe Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 71: Western Europe Market Value (US$ Million) Analysis by Stage, 2018 to 2033
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033
Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 77: Western Europe Market Attractiveness by Therapy, 2023 to 2033
Figure 78: Western Europe Market Attractiveness by Stage, 2023 to 2033
Figure 79: Western Europe Market Attractiveness by End User, 2023 to 2033
Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Eastern Europe Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 82: Eastern Europe Market Value (US$ Million) by Stage, 2023 to 2033
Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Stage, 2018 to 2033
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033
Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 97: Eastern Europe Market Attractiveness by Therapy, 2023 to 2033
Figure 98: Eastern Europe Market Attractiveness by Stage, 2023 to 2033
Figure 99: Eastern Europe Market Attractiveness by End User, 2023 to 2033
Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: APAC Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 102: APAC Market Value (US$ Million) by Stage, 2023 to 2033
Figure 103: APAC Market Value (US$ Million) by End User, 2023 to 2033
Figure 104: APAC Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: APAC Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: APAC Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: APAC Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: APAC Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 109: APAC Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 110: APAC Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 111: APAC Market Value (US$ Million) Analysis by Stage, 2018 to 2033
Figure 112: APAC Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033
Figure 113: APAC Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033
Figure 114: APAC Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 115: APAC Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 116: APAC Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 117: APAC Market Attractiveness by Therapy, 2023 to 2033
Figure 118: APAC Market Attractiveness by Stage, 2023 to 2033
Figure 119: APAC Market Attractiveness by End User, 2023 to 2033
Figure 120: APAC Market Attractiveness by Country, 2023 to 2033
Figure 121: MEA Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 122: MEA Market Value (US$ Million) by Stage, 2023 to 2033
Figure 123: MEA Market Value (US$ Million) by End User, 2023 to 2033
Figure 124: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: MEA Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 129: MEA Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 130: MEA Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 131: MEA Market Value (US$ Million) Analysis by Stage, 2018 to 2033
Figure 132: MEA Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033
Figure 133: MEA Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033
Figure 134: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 135: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 136: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 137: MEA Market Attractiveness by Therapy, 2023 to 2033
Figure 138: MEA Market Attractiveness by Stage, 2023 to 2033
Figure 139: MEA Market Attractiveness by End User, 2023 to 2033
Figure 140: MEA Market Attractiveness by Country, 2023 to 2033
The global Her 2 positive gastric cancer market is likely to reach a valuation of USD 1261.8 Million by the end of 2023.
AstraZeneca, Bayer, Bristol-Myers Squibb, Hutchison Medipharma, LintonPharm are some of the key players in the global HER2 positive gastric cancer market
Sales of HER2 positive gastric cancer market are likely to expand at 3.5% CAGR through 2033.
The US, Canada, Japan, China, & Germany are expected to drive most of the demand for HER2 positive gastric cancer market.
By the end of 2033, the global market for HER2-positive gastric cancer market is predicted to reach a valuation of USD 1779.8 Million
Explore Similar Insights
HER2 Positive Gastric Cancer Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
